Immune checkpoint blockade has transformed immuno-oncology, enabling the immune system to fight cancer more effectively. The PD-1/PD-L1 pathway is a key regulator of immune suppression in tumors, making it a prime target for therapeutic intervention. Inhibiting this pathway restores T cell function, reactivating the body’s natural ability to eliminate cancer cells. Numerous FDA- and EMA-approved PD-1/PD-L1 inhibitors have already revolutionized cancer treatment, and research continues to expand the pipeline of next-generation immune checkpoint inhibitors.

At SYG BIOTECH, we provide next-generation bioassay solutions designed to accelerate the discovery of novel therapeutic proteins. Our unique  smart-bioassay offers an advanced in vitro screening platform for rapid and precise identification of immune checkpoint inhibitors and other therapeutic biomolecules. With a focus on efficiency, accuracy, and scalability, our technology surpasses conventional methods, providing a powerful alternative to existing bioassays.

SYG BIOTECH introduces a breakthrough engineered microcell bioassay, designed to transform PD-1/PD-L1 immune checkpoint screening with unmatched speed, precision, and scalability.

Our Smart-bioassay is designed to facilitate the selection and functional characterization of new molecules targeting the PD-1/PD-L1 immune checkpoint pathway, a crucial target in cancer immunotherapy.

By providing early-stage insights, our bioassay enables data-driven decision-making, accelerating the optimization of lead compounds before advancing to preclinical development.

Our innovative bioassay technology extends beyond PD-1/PD-L1 research. It can be adapted to various therapeutic targets, including:

🔬 VHHs (Nanobodies) & DARPins – Small, stable, and highly specific binding proteins with increasing potential in drug development.
🧬 Peptides & Small Molecules – Optimized for targeted therapies in oncology, autoimmune diseases, and beyond.
🦠 Other Immune Checkpoints – Expanding research capabilities for next-generation immunotherapies.

Why Choose Our Living Microcell Technology?

✅ A Self-Sustaining Living System – Unlike static or synthetic models, our engineered microcells actively participate in PD-1/PD-L1 interactions, offering a biologically relevant and dynamic screening platform.

✅ Instant, Amplified Bioluminescent Readout – Integrated with a high-sensitivity reporter gene, our bioassay generates real-time, quantifiable data for precise immune checkpoint analysis.

✅ No Eukaryotic Cell Culture Required – Say goodbye to time-consuming mammalian cell maintenance. Our system delivers faster, more reliable results with reduced operational complexity.

✅ Designed for High-Throughput Screening – Our scalable, automation-compatible bioassay seamlessly integrates into drug discovery pipelines, accelerating PD-1/PD-L1 inhibitor selection.

Advancing Immunotherapy with Smart Microcell Innovation

As the need for next-generation immunotherapies grows, researchers require faster, more efficient screening solutions. Our living microcell bioassay offers a biologically relevant, cost-effective, and high-throughput alternative to traditional cell-based assays, helping biotech and pharma partners expedite the development of breakthrough PD-1/PD-L1 inhibitors.